Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
AbCellera (Nasdaq: ABCL) and Jazz Pharmaceuticals announced a preclinical collaboration, option and license agreement to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.
AbCellera receives $56 million upfront, up to $28 million for a third program, and may earn up to $792 million per program in potential option, development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
Jazz Pharmaceuticals (Nasdaq:JAZZ) presented 11 late-breaking data sets at SLEEP 2026 on Xywav in narcolepsy and idiopathic hypersomnia. Findings highlight individualized dosing optimization, real-world feasibility in over 13,000 patients, and cardiometabolic markers potentially affected by Xywav’s low-sodium formulation, including blood pressure, lipids, and sodium-related symptoms.
Jazz Pharmaceuticals (Nasdaq:JAZZ) reported top-line Phase 3 LAGOON results for Zepzelca (lurbinectedin) in second-line small cell lung cancer. The trial did not meet its primary overall survival endpoint for Zepzelca alone or with irinotecan versus topotecan/irinotecan. No new safety signals were seen, and safety profiles matched known data.
Overall median OS was 8.7 months (Zepzelca), 10.9 months (Zepzelca+irinotecan), and 10.7 months (control). Jazz said LAGOON does not affect Zepzelca’s U.S. first-line maintenance approval or its 2026 guidance.
Jazz Pharmaceuticals (Nasdaq:JAZZ) will present 21 abstracts, including 11 late-breaking, at SLEEP 2026 (June 14-17, Baltimore) focused on Xywav for narcolepsy and idiopathic hypersomnia.
Presentations cover DUET, LYRICAL, XYLO and other studies on sleep inertia, hypersomnolence, quality of life, cardiovascular biomarkers and individualized low-sodium oxybate dosing.
Jazz (NASDAQ:JAZZ) reported Phase 3 HERIZON-GEA-01 results in HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma using Ziihera (zanidatamab-hrii) plus chemotherapy, with or without Tevimbra (tislelizumab).
Zanidatamab combinations improved median PFS (12.4 vs 8.1 months) and OS (up to 26.4 vs 19.2 months), with consistent benefit across PD-L1 subgroups, including PD-L1-negative patients (OS 29.7 vs 15.8 months). Safety was consistent with known component profiles.
Jazz Pharmaceuticals (Nasdaq:JAZZ) announced that management will join fireside chats at three upcoming investor events: the 2026 RBC Global Healthcare Conference on May 19, 2026 at 8:00 a.m. ET, the Cowen 7th Annual Oncology Innovation Summit on May 27, 2026 at 2:00 p.m. ET, and the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30 a.m. ET.
Audio webcasts will be accessible through the Investors section of Jazz Pharmaceuticals’ website, with replays available for 30 days.
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported 1Q26 results: total revenues $1.07B (+19% YoY), GAAP EPS $4.43 and non-GAAP EPS $6.34, and $408M cash from operations. Zanidatamab sBLA for HER2+ 1L GEA received Priority Review with a PDUFA date of Aug 25, 2026. Xywav, Epidiolex, Zepzelca and Modeyso drove revenue growth. The company reaffirmed 2026 guidance of $4.25–$4.50B revenues and provided ranges for margins, SG&A, R&D and tax rate assumptions.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced FDA acceptance with Priority Review of an sBLA for Ziihera (zanidatamab-hrii) combinations as first-line therapy for adult patients with HER2+ unresectable locally advanced or metastatic gastric, GEJ, or gastroesophageal adenocarcinoma (GEA).
The FDA set a PDUFA target action date of August 25, 2026. The submission uses the RTOR program and is supported by pivotal HERIZON-GEA-01 data showing added benefit when combining zanidatamab with chemotherapy ± tislelizumab. The FDA previously granted Breakthrough Therapy designation for these combinations.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will report 2026 first quarter financial results on May 5, 2026 after U.S. market close. Management will host a webcast at 4:30 p.m. ET to discuss results and provide a business and financial update.
Interested parties may register in advance; a replay will be available via the Investors section of the company website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present clinical and real-world data for Ziihera (zanidatamab-hrii) and Zepzelca (lurbinectedin) at ASCO 2026, May 29–June 2 in Chicago. Presentations include rapid oral PD-L1 subgroup analyses from HERIZON-GEA-01 and IMforte maintenance analyses, plus seven poster presentations across GI, lung and sarcoma sessions.
Highlights include PFS/OS across PD-L1 subgroups, GI tolerability analyses, ctDNA profiling, real-world treatment patterns, and IMforte molecular-subtype outcomes.